Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy

Cancer stem cells (CSCs) are the main drivers of disease progression and chemotherapy resistance in breast cancer. Tumor progression and chemoresistance might then be prevented by CSC-targeted therapies. We previously demonstrated that Toll-like Receptor (TLR)2 is overexpressed in CSCs and fuels the...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Antonino Di Lorenzo, Elisabetta Bolli, Roberto Ruiu, Giuseppe Ferrauto, Enza Di Gregorio, Lidia Avalle, Aurora Savino, Pietro Poggio, Irene Fiore Merighi, Federica Riccardo, Mara Brancaccio, Elena Quaglino, Federica Cavallo, Laura Conti
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Taylor & Francis Group 2022-12-01
Serie:	OncoImmunology
Soggetti:	Breast cancer Toll-like receptor 2 HER2 HMGB1 chemoresistance
Accesso online:	https://www.tandfonline.com/doi/10.1080/2162402X.2022.2086752
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!